Steroid hormones and hormone-related genetic and lifestyle characteristics as risk factors for benign prostatic hyperplasia: Review of epidemiologic literature

Urology

Volumn 64, Issue 2, 2004, Pages 201-211

  Neuhouser, Marian L ^a   Kristal, Alan R ^a,b   Penson, David F ^a,c  

^a USA   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

STEROID HORMONE;

ALCOHOL CONSUMPTION; ANTHROPOMETRY; DIETARY INTAKE; EPIDEMIOLOGICAL DATA; GENETIC POLYMORPHISM; GENETIC TRAIT; HUMAN; LIFESTYLE; MALE; MOLECULAR DYNAMICS; OBESITY; PHYSICAL ACTIVITY; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; PROTEIN FUNCTION; REVIEW; RISK FACTOR; SMOKING; STEROID METABOLISM;

AGED; ALCOHOL DRINKING; CASE-CONTROL STUDIES; COHORT STUDIES; COMORBIDITY; CROSS-SECTIONAL STUDIES; DIET; GENETIC PREDISPOSITION TO DISEASE; GONADAL STEROID HORMONES; HUMANS; LIFE STYLE; MALE; MIDDLE AGED; MOTOR ACTIVITY; OBESITY; PROSTATIC HYPERPLASIA; RECEPTORS, ANDROGEN; RECEPTORS, CALCITRIOL; RISK FACTORS; SMOKING; STEROID 17-ALPHA-HYDROXYLASE; TESTOSTERONE 5-ALPHA-REDUCTASE; TRINUCLEOTIDE REPEATS; UNITED STATES;

EID: 4143118089     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.urology.2004.04.025     Document Type: Review

References (50)

1. Kirby R.S. The natural history of benign prostatic hyperplasia what have we learned in the last decade? Urology. 56:2000;3-6
2. Platz E.A., Smit E., Curhan G.C., et al. Prevalence of and racial/ethnic variation in lower urinary tract symptoms and noncancer prostate surgery in U.S. men. Urology. 59:2002;877-883
3. Barry M.J., Floyd J.F., O'Leary M.P., et al. The American Urological Association symptom index for benign prostatic hyperplasia. J Urol. 148:1992;1549-1557
4. Joseph M.A., Wei J.T., Harlow S.D., et al. Relationship of serum sex-steroid hormones and prostate volume in African American men. Prostate. 53:2002;322-329
5. Chokkalingam A.P., Gao Y.T., Deng J., et al. Insulin-like growth factors and risk of benign prostatic hyperplasia. Prostate. 52:2002;98-105
6. Barry M.J., Cockett A.T., Holtgrewe H.L., et al. Relationship of symptoms of prostatism to commonly used physiological and anatomical measures of the severity of benign prostatic hyperplasia. J Urol. 150:1993;351-358
7. Baine W.B., Yu W., Summe J.P., et al. Epidemiologic trends in the evaluation and treatment of lower urinary tract symptoms in elderly male Medicare patients from 1991 to 1995. J Urol. 160:1998;816-820
8. Hsing A.W. Hormones and prostate cancer what's next? Epidemiol Rev. 23:2001;42-58
9. Meigs J.B., Mohr B., Barry M.J., et al. Risk factors for clinical benign prostatic hyperplasia in a community-based population of healthy aging men. J Clin Epidemiol. 54:2001;935-944
10. Gann P.H., Hennekens C.H., Longcope C., et al. A prospective study of plasma hormone levels, nonhormonal factors and development of benign prostatic hyperplasia. Prostate. 26:1995;40-49
11. Lagiou P., Mantzoros C.S., Tzonou A., et al. Serum steroids in relation to benign prostatic hyperplasia. Oncology. 54:1997;497-501
12. Meikle A.W., Stephenson R.A., McWhorter W.P., et al. Effects of age, sex steroids and family relationships on volumes of prostate zones in men with and without prostate cancer. Prostate. 26:1995;253-259
13. Schatzl G., Brössner C., Schmid S., et al. Endocrine status in elderly men with lower urinary tract symptoms correlation of age, hormonal status, and lower urinary tract function. Urology. 55:2000;397-402
14. Pincus S.M., Mulligan T., Iranmanesh A., et al. Older males secrete luteinizing hormone and testosterone more irregularly, and jointly more asynchronously, than younger males. Proc Natl Acad Sci USA. 93:1996;14100-14105
15. Giovannucci E.L., Stampfer M., Chan A., et al. CAG repeat within the androgen receptor gene and incidence of surgery for benign prostatic hyperplasia in U.S. physicians. Prostate. 39:1999;130-134
16. Giovannucci E., Platz E.A., Stampfer M.J., et al. The CAG repeat within the androgen receptor gene and benign prostatic hyperplasia. Urology. 53:1999;121-125
17. Mitsumori K., Terai A., Oka H., et al. Androgen receptor CAG repeat length polymorphism in benign prostatic hyperplasia (BPH) correlation with adenoma growth. Prostate. 41:1999;253-257
18. Bousema J.T., Bussemakers M.J.G., van Houwelingen K.P., et al. Polymorphisms in the vitamin D receptor gene and the androgen receptor gene and the risk of benign prostatic hyperplasia. Eur Urol. 37:2000;234-238
19. Hamasaki T., Inatomi H., Katoh T., et al. Significance of vitamin D receptor gene polymorphism for risk and disease severity of prostate cancer and benign prostatic hyperplasia in Japanese. Urol Int. 68:2002;226-231
20. Habuchi T., Liqing Z., Suzuki T., et al. Increased risk of prostate cancer and benign prostatic hyperplasia associated with a CYP17 gene polymorphism with a gene dosage effect. Cancer Res. 60:2000;5710-5713
21. Schatzl G., Gsur A., Bernhofer G., et al. Association of vitamin D receptor and 17 hydroxylase gene polymorphisms with benign prostatic hyperplasia and benign prostatic enlargement. Urology. 57:2001;567-572
22. Schatzl G., Madersbacher S., Gsur A., et al. Association of polymorphisms within androgen receptor, 5α-reductase, and PSA genes with prostate volume, clinical parameters, and endocrine status in elderly men. Prostate. 52:2002;130-138
23. Ingles S.A., Ross R.K., Yu M.C., et al. Association of prostate cancer risk with genetic polymorphisms in vitamin D receptor and androgen receptor. J Natl Cancer Inst. 89:1997;166-170
24. Gsur A., Bernhofer G., Hinteregger S., et al. A polymorphism in the CYP17 gene is associated with prostate cancer risk. Int J Cancer. 87:2000;434-437
25. Febbo P.G., Kantoff P.W., Platz E.A., et al. The V89L polymorphism in the 5α-reductase type 2 gene and risk of prostate cancer. Cancer Res. 59:1999;5878-5881
26. Dorgan J.F., Judd J.T., Longcope C., et al. Effects of dietary fat and fiber on plasma and urine androgens and estrogens in men a controlled feeding study. Am J Clin Nutr. 64:1996;850-855
27. 3, inhibits the proliferation of primary prostatic epithelial cells. Cancer Epidemiol Biomarkers Prev. 9:2000;265-270
28. Costello L.C., Franklin R.B. Novel role of zinc in the regulation of prostate citrate metabolism and its implications in prostate cancer. Prostate. 35:1998;285-296
29. Suzuki S., Platz E.A., Kawachi I., et al. Intakes of energy and macronutrients and the risk of benign prostatic hyperplasia. Am J Clin Nutr. 75:2002;689-697
30. Chyou P.H., Nomura A.M., Stemmermann G.N., et al. A prospective study of alcohol, diet, and other lifestyle factors in relation to obstructive uropathy. Prostate. 22:1993;253-264
31. Platz E.A., Rimm E.B., Kawachi I., et al. Alcohol consumption, cigarette smoking, and risk of benign prostatic hyperplasia. Am J Epidemiol. 149:1999;106-115
32. Morrison A.S. Risk factors for surgery for prostatic hypertrophy. Am J Epidemiol. 135:1992;974-980
33. Lagiou P., Wuu J., Trichopoulou A., et al. Diet and benign prostatic hyperplasia a study in Greece. Urology. 54:1999;284-290
34. Signorello L.B., Tzonou A., Lagiou P., et al. The epidemiology of benign prostatic hyperplasia a study in Greece. BJU Int. 84:1999;286-291
35. Gass R. Benign prostatic hyperplasia the opposite effects of alcohol and coffee intake. Br J Urol. 90:2002;649-654
36. Giovannucci E., Pollak M., Liu Y., et al. Nutritional predictors of insulin-like growth factor I and their relationships to cancer in men. Cancer Epidemiol Biomarkers Prev. 12:2003;84-89
37. Chokkalingam A.P., Pollak M., Filmore C.M., et al. Insulin-like growth factors and prostate cancer a population-based case control study in China. Cancer Epidemiol Biomarkers Prev. 10:2001;421-428
38. Roberts R.O., Jacobson D.J., Girman C.J., et al. Insulin-like growth factor 1, insulin-like growth factor binding protein 3, and urologic measures of benign prostatic hyperplasia. Am J Epidemiol. 167:2003;784-791
39. Rohan T., Jain M., Miller A. Alcohol consumption and risk of benign proliferative epithelial disorders of the breast a case-cohort study. Pub Health Nutr. 1:1998;139-145
40. Ida Y., Tsujimaru S., Nakamaura K. Effects of acute and repeated alcohol ingestion on hypothalamic-pituitary-gonadal and hypothalamic-pituitary-adrenal functioning in normal males. Drug Alcohol Depend. 31:1992;57-64
41. Giovannucci E., Rimm E.B., Chute C.G., et al. Obesity and benign prostatic hyperplasia. Am J Epidemiol. 140:1994;989-1002
42. Seitter W.R., Barrett-Connor E. Cigarette smoking, obesity, and benign prostatic hypertrophy a prospective population-based study. Am J Epidemiol. 135:1992;500-503
43. Dahle S.E., Chokkalingam A.P., Gao Y.T., et al. Body size and serum levels of insulin and leptin in relation to the risk of benign prostatic hyperplasia. J Urol. 168:2002;599-604
44. Soygür T., Küpeli B., Adydos K., et al. Effect of obesity on prostatic hyperplasia its relation to sex steroid levels. Int Urol Nephrol. 28:1996;55-59
45. Garaulet M., Perez-Llamas F., Perez-Ayala M., et al. Site-specific differences in the fatty acid composition of abdominal adipose tissue in an obese population from a Mediterranean area relation with dietary fatty acids, plasma lipid profile, serum insulin, and central obesity. Am J Clin Nutr. 74:2001;585-591
46. Subak L.L., Johnson C., Whitcomb E., et al. Does weight loss improve incontinence in moderately obese women? Int Urogynecol J. 13:2002;40-43
47. Platz E.A., Kawachi I., Rimm E.B., et al. Physical activity and benign prostatic hyperplasia. Arch Intern Med. 158:1998;2349-2356
48. Lacey J.V., Deng J., Dosemeci M., et al. Prostate cancer, benign prostatic hyperplasia and physical activity in Shanghai, China. Int J Epidemiol. 30:2001;341-349
49. Irwin M.L., Yasui Y., Ulrich C.M., et al. Effect of exercise on total and intra-abdominal body fat in postmenopausal women. JAMA. 289:2003;323-330
50. Koskimaki J., Hakama M., Huhtala H., et al. Association of smoking with lower urinary tract symptoms. J Urol. 159:1998;1580-1582